Pelizaeus-Merzbacher disease, transitional form

Pelizaeus-Merzbacher disease (PMD), transitional form, is an intermediate clinical variant of Pelizaeus-Merzbacher disease that falls in severity between the classic (type I) and connatal (type II) forms. PMD is a hypomyelinating leukodystrophy caused by mutations in the PLP1 gene located on the X chromosome, which encodes proteolipid protein 1, a major structural component of central nervous system myelin. The transitional form is characterized by deficient myelination of the brain and spinal cord, leading to progressive neurological dysfunction that is more severe than the classic form but less severe than the connatal form. Key clinical features of the transitional form include nystagmus (involuntary eye movements) appearing in early infancy, significant motor developmental delay, progressive spasticity, cerebellar ataxia, and cognitive impairment. Affected individuals typically develop some limited motor milestones such as head control and possibly supported sitting, but independent ambulation is generally not achieved. Stridor and swallowing difficulties may also be present. The disease primarily affects the central nervous system, with MRI showing diffuse hypomyelination of the white matter. There is currently no cure for Pelizaeus-Merzbacher disease, transitional form. Treatment is supportive and symptomatic, focusing on physical therapy, management of spasticity with medications such as baclofen, nutritional support for swallowing difficulties, and seizure management if needed. Experimental approaches including stem cell transplantation and gene therapy are under investigation but remain in early stages. Life expectancy is reduced compared to the general population, though individuals may survive into adolescence or early adulthood with appropriate supportive care.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Pelizaeus-Merzbacher disease, transitional form